196 related articles for article (PubMed ID: 34024901)
1. Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects.
Zhang W; Song Y; Zhang X
Med Sci Monit; 2021 May; 27():e932146. PubMed ID: 34024901
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.
Karami S; Sattarifard H; Kiumarsi M; Sarabandi S; Taheri M; Hashemi M; Bahari G; Ghavami S
Asian Pac J Cancer Prev; 2020 Oct; 21(10):3115-3123. PubMed ID: 33112575
[TBL] [Abstract][Full Text] [Related]
3. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract][Full Text] [Related]
4. Association between
Hashemi M; Karami S; Sarabandi S; Moazeni-Roodi A; Małecki A; Ghavami S; Wiechec E
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31405171
[TBL] [Abstract][Full Text] [Related]
5. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population.
Xie Q; Chen Z; Xia L; Zhao Q; Yu H; Yang Z
Gene; 2018 Oct; 674():188-194. PubMed ID: 29940275
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
8. Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis.
Zou J; Wu D; Li T; Wang X; Liu Y; Tan S
Pathol Res Pract; 2019 Feb; 215(2):229-234. PubMed ID: 30552042
[TBL] [Abstract][Full Text] [Related]
9. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.
Yang J; Meng L; Yang Y; Gao H; Jiang H
Nucleosides Nucleotides Nucleic Acids; 2024; 43(3):230-248. PubMed ID: 37688463
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
11. Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome.
Han R; Gong X; Zhu Y; Liu X; Xia Y; Huang Y; Zhang M; Zhang Y; La X; Ding J
Biomed Res Int; 2021; 2021():9596358. PubMed ID: 33521133
[TBL] [Abstract][Full Text] [Related]
12. Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility.
Qian C; Guo H; Chen X; Shi A; Li S; Wang X; Pan J; Fang C
J Diabetes Res; 2018; 2018():1614683. PubMed ID: 30534571
[TBL] [Abstract][Full Text] [Related]
13. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.
Tan D; Sheng L; Yi QH
Cancer Biomark; 2018 Feb; 21(2):287-297. PubMed ID: 29171986
[TBL] [Abstract][Full Text] [Related]
14. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
15. Are programmed cell death 1 gene polymorphisms correlated with susceptibility to rheumatoid arthritis?: A meta-analysis.
Zou Y; Zhang Z; Liu Y; Liu D; Xu W
Medicine (Baltimore); 2017 Sep; 96(35):e7805. PubMed ID: 28858091
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Liu D; Wang S; Bindeman W
J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
[TBL] [Abstract][Full Text] [Related]
17. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
18. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
19. PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population.
Zang B; Chen C; Zhao JQ
Aging (Albany NY); 2020 Feb; 12(4):3771-3790. PubMed ID: 32084010
[No Abstract] [Full Text] [Related]
20. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
